// App-Quantinova.ai

2698 : Reasons for Initiation of Canakinumab of Patients with Systemic Juvenile Idiopathic Arthritis: A Retrospective Medical Chart Review from the United States

Researchers

Presenter

  • Raluca Ionescu-Ittu

Principal Investigators

  • Ameur M. Manceur

  • Kathleen G. Lomax

  • Jordan Cammarota

  • Jipan Xie

  • Navneet Sanghera

  • Alexei A. Grom

Medical Centers

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Analysis Group, Inc., Montreal, QC, Canada

  • Analysis Group Inc.,, Washington, DC

  • Analysis Group, Inc., Los Angeles, CA

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Division of Nephrology, Cincinnati Childrens Hospital Medical Center, Cincinnati, OH

Locations

  • United States

  • Canada

Companies

  • Novartis AG

  • Analysis Group, Inc.

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • canakinumab (SC)

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved